CelLBxHealth报告,对治疗慢性炎的新细胞疗法的早期结果充满希望,在一次小试验中没有副作用。 CelLBxHealth reports promising early results for a new cell therapy treating chronic inflammation, with no side effects in a small trial.

CelLBxhealth PLC宣布对针对慢性炎症的新型细胞治疗进行概念证明研究取得积极成果。 CelLBxHealth PLC has announced positive results from a proof-of-concept study on a novel cell-based therapy targeting chronic inflammatory conditions. 这次试验涉及一小批病人,表明在关键生物标志和减少症状方面有可衡量的改进。 The trial, involving a small group of patients, demonstrated measurable improvements in key biomarkers and symptom reduction. 该公司表示,调查结果支持进一步研制治疗方法,尽管还需要进行更大的随机测试,以确认功效和安全性。 The company says the findings support further development of the treatment, though larger, randomized trials are needed to confirm efficacy and safety. 在本研究期内,没有发生任何不利事件的报告。 No adverse events were reported during the study period.